<?xml version="1.0" encoding="UTF-8"?><iati-activities generated-datetime="2026-11-04T21:06:34.7322734+00:00" version="2.03"><iati-activity last-updated-datetime="2026-07-31T00:00:00+00:00" xml:lang="en" default-currency="USD" hierarchy="1"><iati-identifier>GB-CHC-1099776-Y6</iati-identifier><reporting-org xml:lang="en" ref="GB-CHC-1099776" type="21"><narrative>Malaria Consortium</narrative></reporting-org><title xml:lang="en"><narrative>Improving Vitamin A Coverage through integration with Seasonal Malaria Chemoprevention delivery: An Implementation Research in rural and urban settings in Nigeria</narrative></title><description xml:lang="en" type="1"><narrative>Project ID number HCE013 -IRS022 :'Improving Vitamin A Coverage through integration with Seasonal Malaria Chemoprevention delivery: An Implementation Research in rural and urban settings in Nigeria' This study aims to provide additional evidence to support policy makers’ decision-making regarding full integration of VAS with SMC campaigns at scale and in diverse settings. Study objectives and research questions: The objectives are to design and implement in collaboration with key stakeholders, an integrated SMC plus VAS campaign at scale and in diverse settings in Bauchi state; assess the feasibility and acceptability of integration among caregivers, field implementers, and policy makers; develop and implement a research uptake plan; and provide policy makers with evidence to inform decision-making about integrating SMC and VAS in Nigeria. The primary research question is: What is the effect of full integration of SMC and VAS at scale on vitamin A coverage, SMC coverage, safety, equity, efficiency and cost?</narrative></description><participating-org xml:lang="en" type="21" role="1"><narrative>Medicines for Malaria Venture</narrative></participating-org><participating-org xml:lang="en" type="21" role="1"><narrative>Task Force Global Health</narrative></participating-org><activity-status code="4" /><activity-date type="2" iso-date="2021-05-01" /><activity-date type="3" iso-date="2022-07-31" /><activity-date type="4" iso-date="2022-07-31" /><contact-info type="1"><organisation><narrative>Malaria Consortium</narrative></organisation><person-name><narrative>Malaria Consortium</narrative></person-name><email>iati@malariaconsortium.org</email><mailing-address><narrative>The Green House, 244-254 Cambridge Heath Road, London, E2 9DA, United Kingdom</narrative></mailing-address></contact-info><recipient-country code="NG" percentage="100.000000000000000000" /><sector vocabulary="1" code="12240" percentage="100.000000000000000000"><narrative>Basic nutrition</narrative></sector><default-flow-type code="10" /><default-finance-type code="110" /><default-tied-status code="5" /><budget type="1"><period-start iso-date="2021-05-01" /><period-end iso-date="2022-07-31" /><value value-date="2021-05-01" currency="USD">150000</value></budget><transaction><transaction-type code="1" /><transaction-date iso-date="2021-06-30" /><value currency="USD" value-date="2021-06-30">104960</value><provider-org><narrative>Task Force Global Health</narrative></provider-org><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="1" /><transaction-date iso-date="2021-07-16" /><value currency="USD" value-date="2021-07-16">505909</value><provider-org><narrative>Medicines for Malaria Venture</narrative></provider-org><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="1" /><transaction-date iso-date="2022-04-20" /><value currency="USD" value-date="2022-04-20">30000</value><provider-org><narrative>Task Force Global Health</narrative></provider-org><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="1" /><transaction-date iso-date="2022-12-16" /><value currency="USD" value-date="2022-12-16">15000</value><provider-org><narrative>Task Force Global Health</narrative></provider-org><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="2" /><transaction-date iso-date="2021-05-01" /><value currency="USD" value-date="2021-05-01">150000</value><provider-org><narrative>Task Force Global Health</narrative></provider-org><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><related-activity ref="GB-CHC-1099776-Y6-NG" type="2" /></iati-activity><iati-activity last-updated-datetime="2026-07-31T00:00:00+00:00" xml:lang="en" default-currency="USD" hierarchy="2"><iati-identifier>GB-CHC-1099776-Y6-NG</iati-identifier><reporting-org xml:lang="en" ref="GB-CHC-1099776" type="21"><narrative>Malaria Consortium</narrative></reporting-org><title xml:lang="en"><narrative>Improving Vitamin A Coverage through integration with Seasonal Malaria Chemoprevention delivery: An Implementation Research in rural and urban settings in Nigeria [Nigeria]</narrative></title><description xml:lang="en" type="1"><narrative>Project ID number HCE013 -IRS022 :'Improving Vitamin A Coverage through integration with Seasonal Malaria Chemoprevention delivery: An Implementation Research in rural and urban settings in Nigeria' This study aims to provide additional evidence to support policy makers’ decision-making regarding full integration of VAS with SMC campaigns at scale and in diverse settings. Study objectives and research questions: The objectives are to design and implement in collaboration with key stakeholders, an integrated SMC plus VAS campaign at scale and in diverse settings in Bauchi state; assess the feasibility and acceptability of integration among caregivers, field implementers, and policy makers; develop and implement a research uptake plan; and provide policy makers with evidence to inform decision-making about integrating SMC and VAS in Nigeria. The primary research question is: What is the effect of full integration of SMC and VAS at scale on vitamin A coverage, SMC coverage, safety, equity, efficiency and cost? [Nigeria]</narrative></description><participating-org xml:lang="en" ref="GB-CHC-1099776" type="21" role="4"><narrative>Malaria Consortium</narrative></participating-org><activity-status code="4" /><activity-date type="2" iso-date="2021-05-01" /><activity-date type="3" iso-date="2022-07-31" /><activity-date type="4" iso-date="2022-07-31" /><contact-info type="1"><organisation><narrative>Malaria Consortium</narrative></organisation><person-name><narrative>Malaria Consortium</narrative></person-name><email>iati@malariaconsortium.org</email><mailing-address><narrative>The Green House, 244-254 Cambridge Heath Road, London, E2 9DA, United Kingdom</narrative></mailing-address></contact-info><recipient-country code="NG" percentage="100.000000000000000000" /><sector vocabulary="1" code="12240" percentage="100.000000000000000000"><narrative>Basic nutrition</narrative></sector><default-flow-type code="10" /><default-finance-type code="110" /><default-tied-status code="5" /><transaction><transaction-type code="4" /><transaction-date iso-date="2021-06-30" /><value currency="USD" value-date="2021-06-30">213</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2021-09-30" /><value currency="USD" value-date="2021-09-30">19277</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2021-12-31" /><value currency="USD" value-date="2021-12-31">79554</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2022-03-31" /><value currency="USD" value-date="2022-03-31">13620</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2022-06-30" /><value currency="USD" value-date="2022-06-30">19597</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2022-09-30" /><value currency="USD" value-date="2022-09-30">8842</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2022-12-13" /><value currency="USD" value-date="2022-12-13">9292</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><transaction><transaction-type code="4" /><transaction-date iso-date="2023-03-31" /><value currency="USD" value-date="2023-03-31">-394</value><disbursement-channel code="2" /><flow-type code="10" /><finance-type code="110" /><tied-status code="5" /></transaction><related-activity ref="GB-CHC-1099776-Y6" type="1" /></iati-activity></iati-activities>
